NPC1 variants are not associated with Parkinson’s Disease, REM-sleep behaviour disorder or Dementia with Lewy bodies in European cohorts

1. Introduction

Alpha synucleinopathies are a group of neurodegenerative disorders characterized by alpha-synuclein and Lewy body accumulation in the brain. These disorders include mainly Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and their prodromal rapid-eye-movement (REM)-sleep behavior disorder (RBD). Alpha-synucleinopathies have complex etiology and may show overlap with other disorders. One such group of disorders is lysosomal storage disorders (LSDs), characterized by a lysosomal accumulation of undegraded substrates, often due to the dysfunction of various lysosomal enzymes (Filocamo and Morrone, 2011). Many commonalities have been observed in both groups, including alpha-synuclein deposits in the brain, substantia nigra pathology, lysosomal dysfunction, lipid metabolism alterations, and impairment of the ubiquitin-proteasome system (Shachar et al., 2011). Additionally, a number of genes, including GBA, SMPD1, ASAH1 and GALC, have been identified as contributors to both alpha-synucleinopathies and LSDs (Alcalay et al., 2019; Deane et al., 2011; Nalls et al., 2019; Riboldi and Di Fonzo, 2019; Robak et al., 2017).

Biallelic mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene lead to Niemann-Pick disease Types A and B, and heterozygous SMPD1 variants have been associated with PD and DLB (Alcalay et al., 2019; Clark et al., 2015; Desnick et al., 2010). The third class of Niemann-Pick disease, Type C (NPC), is caused by variants in the NPC intracellular cholesterol transporter 1 gene (NPC1). NPC has also been connected to synucleinopathies, as multiple NPC1 variant carriers have been reported to display PD symptoms and Lewy body deposits in the brain (Chiba et al., 2013; Josephs et al., 2004; Kluenemann et al., 2013; Schneider et al, 2019). A genetic study has attempted to examine the relationship between NPC1 variants and PD, finding no association (Ouled Amar Bencheikh et al., 2020). However, this study may have been underpowered and did not examine associations with other synucleinopathies.

In the present study we aimed to further elucidate the role of NPC1 in alpha-synucleinopathies, by testing if common and rare variants in NPC1 were associated with PD, DLB and RBD in a total of 6,546 patients and 6,551 controls.

2. Methods

3. Results

The average coverage of NPC1 sequencing reads was 903x. We included reads with coverage above 50x, which comprised 96% of all NPC1 reads. The number of cases and controls after quality control for each cohort can be found in Table 1. There were 4, 94 and 120 common NPC1 variants (Supplementary Table 1) tested for association with RBD, PD and DLB, respectively. There were 57, 324 and 1924 rare NPC1 variants, tested for association with RBD, PD and DLB (Supplementary Table 2). None of the individual common or rare variants were associated with any of the disease phenotypes after multiple testing correction (Supplementary Table 1 and 2). Additionally, no variant categories in the SKAT-O analyses were associated (Table 2).

In total, we found 17 variants identified predominantly as pathogenic or likely pathogenic for NPC1 across our three cohorts. All of these variants were rare, with none showing association individually or when grouped together in the SKAT-O analyses (Supplementary Table 2).

We also investigated variants linked to the appearance of PD-like symptoms in NPC patients and NPC1 variant carriers (Chiba et al., 2013; Josephs et al., 2004; Kluenemann et al., 2013; Schneider et al, 2019). A total of 75 cases and 57 controls were carriers of p.N222S (rs55680026) across all cohorts, with the variant being more common in controls in RBD and more common in cases in PD and DLB. The variant p.I1061T (rs80358259) was carried by 6 cases and 2 controls, being found more commonly in cases in PD and only in cases in DLB. There were 6 cases and 6 controls with p.S1004L (rs150334966), which was more common in cases than controls in PD and more common in controls than cases in DLB. Variants p.G992R and p.P1007A (rs80358254 and rs80358257) were found in the DLB cohort as well, but only in 1 control and 2 cases, respectively. Despite many of these variants being more frequent in cases, none were found to be significantly associated within any cohort. Further carrier details and association statistics can be found in Supplementary Table 2.

4. Discussion

In the present study, we performed thorough genetic association testing of NPC1 in three cohorts of alpha synucleinopathies - RBD, PD and DLB. We did not find any association between NPC1 variants and these disorders, supporting that NPC1 does not play a major role in alpha synucleinopathies. Our results also support the previously mentioned study on NPC1 and PD, which included an independent PD cohort and found no association of common and rare variants with disease risk (Ouled Amar Bencheikh et al., 2020).

Several cases of individuals who carried NPC1 variants and had PD symptoms and Lewy bodies have been reported (Chiba et al., 2013; Josephs et al., 2004; Kluenemann et al., 2013; Schneider et al, 2019). However, none of the variants in our cohorts were associated with any synucleinopathy. Our findings, together with previous studies (Ouled Amar Bencheikh et al., 2020, Zech et al., 2013), suggest that heterozygous NPC1 variants are unlikely to be an important risk factor for PD symptoms.

The lack of association of NPC1 variants with alpha synucleinopathies, despite the demonstrated association of SMPD1 with PD and DLB, could be due to biological pathway differences (Alcalay et al., 2019; Clark et al., 2015). SMPD1 produces a lysosomal enzyme that breaks down sphingomyelin in the sphingolipid metabolism pathway (Rudakou et al., 2020).

Many genes that have been firmly shown to associate with synucleinopathies are in the same pathway, including GBA, GALC, SMPD1, and ASAH1. NPC1, however, is not in this pathway, and instead is responsible for the trafficking of cholesterol and lipids into the lysosome (Bosch and Kielian, 2015). Thus, the lack of association of NPC1 with synucleinopathies supports that specific dysfunction of the sphingolipid metabolism pathway may be the key lysosomal disease mechanism in synucleinopathies.

This study has a few key limitations. First, we only included individuals of European ancestry, as there was no sufficient available genetic data from non-European populations to perform these analyses. The synucleinopathies included in the present study are complex disorders, thus it is possible that NPC1 variants may contribute to RBD, DLB or PD in other populations. Another limitation is that there are differences in age and sex between patients and controls across all three cohorts. Both common and rare variant analyses were adjusted for sex and age to account for these differences. Lastly, our study cannot rule out the role of very rare NPC1 variants in alpha-synucleinopathies, or variants not present in our cohorts. Rare variants present in only a few cases or controls, such as p.I1061T, p.G992R, and p.P1007A, should be inspected in a larger cohort to confidently determine their lack of association.

In conclusion, our results do not support a major role for NPC1 in RBD, PD and DLB. However, larger studies will be required to definitively rule out NPC1 as a contributing factor.

6. Conflicts of interest

ZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, UCB, Guidepoint, Lighthouse and Deerfield.